| Literature DB >> 33209990 |
Jasdeep Singh1,2, Jasdeep Kaur Dhanoa1, Ratan K Choudhary1, Amarjit Singh3, Ram Saran Sethi1, Simarjeet Kaur4, Chandra Sekhar Mukhopadhyay1.
Abstract
BACKGROUND: MicroRNAs play key roles in host-pathogen-interactions and disease pathogenesis. Our aim was to characterize the differentially expressed miRNAs in the blood cells of diseased (Brucellosis-positive, Johne's disease-positive) and healthy- water buffaloes. The pooled small-RNA samples of each group were sequenced on Ion Torrent Personal Genome Machine (PGM) sequencer and the data were analyzed for differential expression.Entities:
Keywords: Brucellosis; Bubalus bubalis; Johne’s disease; microRNA, RNA-Seq
Year: 2020 PMID: 33209990 PMCID: PMC7242893 DOI: 10.1186/s41544-020-00049-y
Source DB: PubMed Journal: ExRNA ISSN: 2398-0060
Sequence and reason of selection of the differentially expressed miRNAs used for validation
| 1 | bta-miR-9-5p | BbuMir16-F | ucuuugguuaucuagcug | To compare Br-Mu with Ctrl-Mu |
| 2 | bta-miR-677 | BbuMir19-F | cucacugaugagcagcuu | |
| 3 | bta-miR-331-3p | BbuMir18-F | gccccugggccuauccua | To compare JD-Mu with Ctrl-Mu |
| 4 | bta-miR-2440 | BbuMir21-F | ugcagugaugagacccug | |
| 5 | Endogenous Control | BbuRNU6 | acgcaaauucgugaagcguu |
aBr-Mu: Brucella infected buffaloes of Murrah breed
JD-Mu: Johne’s Disease infected buffaloes of Murrah breed
Ctrl-Mu: Healthy buffaloes of Murrah breed
Detail of the designed primers used for qPCR validation of the selected miRNA-target genes vis-à-vis their functions
| 1 | bta-miR-9-5p | Y-Box Binding Protein 3 (YBX3) | Associated with binding of nucleic acid, activation of transcription factor, Sertoli-Sertoli cell junction related pathways | YBX3-F: ccgcaatgccggtgagattg | 62 | 187 |
| YBX3-R: gtttggaccattggccgctt | 62 | |||||
| 2 | bta-miR-9-5p | Sorting Nexin 25 (SNX25) | Phosphatidylinositol binding and type I transforming growth factor beta receptor binding. | SNX25-F: aaatgcgccaaaacccgaca | 62 | 185 |
| SNX25-R: gcatttgctcgccgttctct | 62 | |||||
| 3 | bta-miR-677 | Nuclear Receptor Subfamily 3, Group C, Member 1 (NR3C1) | As transcription factor and also as regulator of transcription factor; | NR3C1-F: acctacgcagtgaaatgtcagact | 62 | 162 |
| NR3C1-R: gtttctccatatttggcattgctgt | 60 | |||||
| 4 | bta-miR-677 | Transmembrane 9 Superfamily Member 3 (TM9SF3) | Regulation of gene expression, morphogenesis, and differentiation, cell cycle progression. | TM9SF3-F: cgctatggtgtgtggcactg | 62 | 170 |
| TM9SF3-R: gctgacctgacagatttcggc | 62 | |||||
| 5 | bta-miR-331-3p | Benzodiazepine Receptor (Peripheral) Associated Protein 1 (BZRAP1) | GPCR & downstream signaling of B Cell Receptor. | BZRAP1-F: acggctgtgctggagaactt | 62 | 182 |
| BZRAP1-R: caggcgatctcggcagatgt | 62 | |||||
| 6 | bta-miR-331-3p | Cleavage and Polyadenylation Specific Factor 2, 100 kDa (CPSF2) | Gene expression and mRNA splicing pathways; RNA binding. | CPSF2-F: cgctgctgaaccaacgtcag | 62 | 187 |
| CPSF2-R: cggtccaacaacaacaatccaaa | 60 | |||||
| 7 | bta-miR-2440 | RAB39B, Member RAS Oncogene Family (RAB39B) | Encodes a member of the Rab family of proteins that are involved in vesicular trafficking. | RAB39B-F: acacgtccagccctaccaaa | 61 | 189 |
| RAB39B-R: aatagcgtctcgggctgacg | 62 | |||||
| 8 | bta-miR-2440 | Ribosomal Modification Protein RimK-Like Family Member A (RIMKLA) | Metabolism pathways and Alanine, aspartate and glutamate metabolism; glutathione synthase activity and N-acetyl-L-aspartate-L-glutamate ligase activity | RIMKLA-F: ccttcgaccaggcatgcaac | 62 | 175 |
| RIMKLA-R: tagacgctctccgcaactcc | 62 |
Number of filtered reads number of reads matched to miRbase vis-à-vis total known and novel mature-star miRNAs identified in the four experimental samples
| 2,676,675 | 89,577 | 258 | 25 | ||
| 2,288,179 | 153,334 | 228 | 23 | ||
| 198,993 | 94,798 | 232 | 12 |
Br-Mu: Brucellosis positive Murrah buffalo
JD-Mu: Johne’s Disease positive Murrah buffalo
Ctrl-Mu: Healthy buffaloes (Control group) of Murrah breed mature* miRNAs: mature miRNAs that originate from alternative or less expressed strand of precursor miRNA hairpin structure
Fig. 1Venn diagrams representing common and unique miRNAs across the three groups a) Brucellosis-positive buffaloes b) Johne’s disease-positive buffaloes c) Healthy buffaloesprepared using an online tool (http://bioinformatics.psb.ugent.be/webtools/Venn)
Fig. 2Box-plot showing an abundance of known miRNAs across diseased and healthy control samples. The overall abundance of 275 known miRNAs expressed as log-transformed FPKM values distributed across the three groups a) Brucellosis-positive buffaloes b) Johne’s disease-positive buffaloes c) Healthy buffaloes; shown as a box plot. The central line inside the boxes indicate median values, box width indicates 25 and 75% quartile ranges around the median, the termini indicate the 2.5 and 97.5 percentiles of the data, and the dots represent outliers
Fig. 3Heatmap of known miRNA expression across the diseased and control samples. The log expression levels of the known miRNAs (i.e. having taurine homolog) across the three groups viz. Brucellosis-positive buffaloes, Johne’s disease-positive buffaloes and Healthy buffaloes; are depicted by the heatmap. The color scale bar (white-orange-red) indicate increasing expression levels (low-medium-high)
Fig. 4Gene Ontology (GO) based classification of the miRNA targets. A total of 937 predicted miRNA-target genes were functionally classified into various categories biological processes (a) and molecular functions (b) using PANTHER Classification System (http://pantherdb.org/)
Fig. 5Relative expression profiles of selected miRNAs and the corresponding target genes. The real-time expression of the four selected miRNAs viz. bta-miR-9-5p, bta-miR-677, bta-miR-331-3p, and bta-miR-2440 were analyzed and normalized against endogenous control BbuRNU6. Two target genes for each of the above-selected four miRNAs, i.e. 8 target genes, were analyzed and gene expression was normalized against two endogenous controls: GAPDH and beta-actin and represented as fold change in diseased vs. control group. Asterisks indicate statistically significant differences (*p < 0.05) in diseased vs. healthy control group. The table indicating P values is included in the figure